IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0242-2024

Sarah Cullivan, Leon Genecand, Natalia El-Merhie, Alison MacKenzie, Mona Lichtblau

{"title":"Inhaled treprostinil in group 3 pulmonary hypertension associated with lung disease: results of the INCREASE and PERFECT studies.","authors":"Sarah Cullivan, Leon Genecand, Natalia El-Merhie, Alison MacKenzie, Mona Lichtblau","doi":"10.1183/20734735.0242-2024","DOIUrl":"10.1183/20734735.0242-2024","url":null,"abstract":"Group 3 pulmonary hypertension (PH) associated with lung disease is a common cause of PH and is associated with substantial morbidity and mortality. Multiple studies of pulmonary arterial hypertension (PAH) therapies in this population have demonstrated conflicting results regarding their safety and efficacy, and therefore the optimum treatment for this group is unknown. The INCREASE and PERFECT randomised, double-blind, placebo-controlled trials attempted to address this unmet need by exploring the role of inhaled treprostinil (iTRE) in PH associated with interstitial lung disease (PH-ILD) and PH associated with COPD (PH-COPD), respectively. In the INCREASE and PERFECT studies individuals were randomised to placebo or iTRE, which was administered via an ultrasonic, pulsed-delivery nebuliser to a maximum dose of 72 μg, four times a day. The INCREASE study randomised 326 subjects with PH-ILD over a 16-week period and met its primary endpoint of change in 6-min walk distance, with a treatment effect of +31.12 m (p<0.001). Reduced disease progression events and increased forced vital capacity were also reported in the treatment arm in a post hoc analysis. By contrast, the PERFECT study was stopped prematurely by the data and safety monitoring committee due to evidence that iTRE increased serious adverse events in subjects with PH-COPD. This journal club provides an overview of these important trials and highlights pertinent unanswered questions in this field.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 1","pages":"240242"},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary veno-occlusive disease: a clinical review. 肺静脉闭塞症：临床回顾。

IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0098-2024

Himanshu Deshwal, Sauradeep Sarkar, Atreyee Basu, Bilal A Jalil

{"title":"Pulmonary veno-occlusive disease: a clinical review.","authors":"Himanshu Deshwal, Sauradeep Sarkar, Atreyee Basu, Bilal A Jalil","doi":"10.1183/20734735.0098-2024","DOIUrl":"10.1183/20734735.0098-2024","url":null,"abstract":"Pulmonary vasculopathy presents as a spectrum of diseases affecting the precapillary pulmonary arterioles, the capillaries and the venules. Pulmonary veno-occlusive disease (PVOD) is classified under group 1 pulmonary arterial hypertension (PAH) as subgroup 1.5 (PAH with features of capillary/venous involvement), and represents a progressive and fatal spectrum of pulmonary vascular disorders. PVOD and pulmonary capillary haemangiomatosis (PCH) can be clinically indistinguishable and often coexist, along with the same risk factors and genetic alterations; they are referred to together as PVOD/PCH in the literature. For brevity, we use the clinical term PVOD in this article. PVOD cannot be distinguished from other forms of PAH based on symptoms and haemodynamics. Risk factors include exposure to toxins/chemotherapeutic drugs and genetic mutation in the EIF2AK4 gene. Radiographic features such as mediastinal adenopathy, centrilobular ground-glass opacities, and interlobular septal thickening, along with the presence of hypoxia and reduced diffusion capacity of the lung may be required for a clinical diagnosis of PVOD, as lung biopsy carries a high risk for bleeding. Characteristic histological findings include narrowing/occlusion of small pulmonary veins. The development of pulmonary oedema with pulmonary vasodilator therapy limits therapeutic options for PVOD. With limited treatment options, lung transplantation remains the only curative treatment.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 1","pages":"240098"},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Malignant pleural mesothelioma associated with recurrent pneumothorax. 恶性胸膜间皮瘤伴复发性气胸。

IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0226-2024

Leher Gumber, Cheng Hong Lim, Muhammad Hashim Naseer, Helen Wallace, Leah Taylor, Sean Parker, David Cooper, Karl Jackson, Joe Thekkudan, Ang Keng, Avinash Aujayeb

引用次数: 0

Update in tuberculosis treatment: a scoping review of current practices. 结核病治疗的最新进展：对当前做法的范围审查。

IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0232-2024

Sofia R Lopes, Mariana Marçal, Nicole Fernandes, Filipa Silva, Pedro Barbosa, Mariana Vieira, João Pedro Ramos, Raquel Duarte

{"title":"Update in tuberculosis treatment: a scoping review of current practices.","authors":"Sofia R Lopes, Mariana Marçal, Nicole Fernandes, Filipa Silva, Pedro Barbosa, Mariana Vieira, João Pedro Ramos, Raquel Duarte","doi":"10.1183/20734735.0232-2024","DOIUrl":"10.1183/20734735.0232-2024","url":null,"abstract":"Background: Tuberculosis (TB) remains a significant global health challenge despite ongoing control efforts, particularly in the context of drug-resistant TB (DR-TB), where treatment success rates remain low, underscoring the need for new therapeutic options. This review synthesises current evidence, since the publication of the World Health Organization guidelines in 2022, on the safety and efficacy of existing and new regimens for drug-susceptible TB (DS-TB) and DR-TB in adults and children.Methods: A comprehensive search was performed across three databases for studies published between January 2022 and February 2024, focusing on current and new TB treatment regimens. Additional backward and forward citation searches were conducted to identify relevant literature.Results: 35 studies were included, evaluating the efficacy, safety and economic impact of new oral regimens for DS-TB and DR-TB. Regimens based on bedaquiline or delamanid demonstrated high success rates and good tolerability. The BPaLM (bedaquiline, pretomanid, linezolid and moxifloxacin) regimen was more effective and safer than the standard care, while shorter DR-TB regimens reduced costs and increased success rates. However, shorter regimens for DS-TB were associated with increased drug costs. Though limited, paediatric studies suggest that shorter, safer regimens may benefit children.Conclusion: Evidence supports the adoption of shorter treatment regimens for both DR-TB and DS-TB to improve safety, effectiveness and cost-effectiveness, particularly in resource-limited settings.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 1","pages":"240232"},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

I just hurt myself out in the garden… right? 我刚刚在花园里弄伤了自己，对吧？

IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0179-2024

Christopher Blanchflower, Farheena Mohammed, Robin Brittain-Long, Ratna Alluri

引用次数: 0

Community led lung health support groups: processes, perspectives and roles for researchers. 社区领导的肺部健康支持小组：研究人员的过程、观点和角色。

IF 2.3

Breathe Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0187-2024

Shannon Sibbald, Monique Barber, Karen Urbshott, Ekam Buttar

引用次数: 0

Unmasking the unexpected: an unusual cause of refractory chronic cough. 揭开意外的面纱：难治性慢性咳嗽的不寻常原因。

IF 2.3

Breathe Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0185-2024

James Wingfield Digby, Jenny King, Haval Balata, Jacky Smith, Paul Marsden

引用次数: 0

Benefits of participating in the Lung Science Conference for early career respiratory experts. 参加肺科学会议对早期职业呼吸专家的好处。

IF 2.3

Breathe Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0290-2024

Anja Schweikert, Antonella F M Dost, Heleen Demeyer, Sara Cuevas Ocaña

引用次数: 0

Diagnosis and management of comorbid disease in COPD. 慢性阻塞性肺病合并症的诊断和治疗。

IF 2.3

Breathe Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0099-2024

Eleanor Cronin, Breda Cushen

引用次数: 0

Diaphragm dysfunction: how to diagnose and how to treat? 隔膜功能障碍：如何诊断和治疗？

IF 2.3

Breathe Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0218-2024

Filipa Jesus, Anda Hazenberg, Marieke Duiverman, Peter Wijkstra

{"title":"Diaphragm dysfunction: how to diagnose and how to treat?","authors":"Filipa Jesus, Anda Hazenberg, Marieke Duiverman, Peter Wijkstra","doi":"10.1183/20734735.0218-2024","DOIUrl":"10.1183/20734735.0218-2024","url":null,"abstract":"The diaphragm, crucial for respiratory function, is susceptible to dysfunction due to various pathologies that can affect the nervous system, neuromuscular junction or the muscle itself. Diaphragmatic dysfunction presents with symptoms ranging from exertional dyspnoea to respiratory failure, significantly impacting patients' quality of life. Diagnosis involves clinical evaluation complemented by imaging and pulmonary function tests. Chest radiography, fluoroscopy, and ultrasonography are pivotal in assessing diaphragmatic movement and excursion, offering varying sensitivities and specificities based on the type and severity of dysfunction. Ultrasonography emerges as a noninvasive bedside tool with high sensitivity and specificity, measuring diaphragm thickness, thickening fraction, and excursion, and enabling monitoring of disease progression and response to treatment over time. Treatment strategies depend on the underlying aetiology and severity, ranging from conservative management to interventions such as surgical plication or diaphragmatic pacing. Ventilatory support, particularly noninvasive ventilation, plays a pivotal role in treatment, enhancing lung function and patient outcomes across unilateral and bilateral dysfunction. Despite advances in diagnostic techniques, awareness and systematic evaluation of diaphragmatic function remain inconsistent across clinical settings. This review consolidates the current understanding of diaphragmatic dysfunction, highlighting diagnostic modalities and treatment options to facilitate early recognition and management of this entity.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 1","pages":"240218"},"PeriodicalIF":2.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breathe最新文献